Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P10523
UPID:
ARRS_HUMAN
Alternative names:
48 kDa protein; Retinal S-antigen; Rod photoreceptor arrestin
Alternative UPACC:
P10523; A0FDN6; Q53SV3; Q99858
Background:
S-arrestin, also known as 48 kDa protein, Retinal S-antigen, and Rod photoreceptor arrestin, plays a crucial role in the visual process. It binds to photoactivated, phosphorylated RHO, terminating RHO signaling via G-proteins by competing with G-proteins for the same binding site on RHO. This action is essential in preventing light-dependent degeneration of retinal photoreceptor cells.
Therapeutic significance:
S-arrestin is implicated in several retinal disorders, including Night blindness, congenital stationary, Oguchi type 1, and Retinitis pigmentosa (RP) types 47 and 96. These conditions highlight the protein's critical role in visual impairment diseases, making it a potential target for therapeutic intervention to restore vision or slow the progression of these disorders.